Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment

Key Points

• Response noted in platinum-resistant ovarian cancer across 40 patients, demonstrating a notable efficacy with bevacizumab.
• 49% of patients showed partial or complete response to the treatment, indicating a significant impact.
• Observational analysis of treatment combining bevacizumab with single-agent chemotherapy.
• Findings highlight the promise of this combination therapy, but results must be validated in larger, controlled trials.